Item 7.01. Regulation FD Disclosure.
On June 11, 2021, Forma Therapeutics Holdings, Inc. (the "Company") issued a
press release titled "Forma Therapeutics Presents New Phase 1 Data on Etavopivat
(formerly referred to as FT-4202) at 26th European Hematology Association
Congress," a copy of which is furnished herewith as Exhibit 99.1 to this Current
Report on Form 8-K.
In addition, the Company has made available on its website the Company's
presentation from the 2021 European Hematology Association's ("EHA") Virtual
Congress. The presentation has been added to the Company's website at
https://ir.formatherapeutics.com/. A copy of the presentation is furnished
herewith as Exhibit 99.2 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached
hereto, is intended to be furnished and shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except
as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On June 11, 2021, the Company announced new data from its ongoing Phase 1 trial
of etavopivat (formerly referred to as FT-4202). The announcement included
initial data from the open-label extension ("OLE") cohort studying etavopivat's
effects on hematologic and hemolytic parameters for patients living with sickle
cell disease ("SCD") receiving 400 mg etavopivat once-daily for at least two
weeks and up to 12 weeks. Also announced were the unblinded results from two
multiple ascending dose ("MAD") cohorts, which demonstrated the effects
once-daily dosing of 300 mg or 600 mg etavopivat for 14 days on measures of
sickle red blood cell ("RBC") functional health.
Clinical Data Results
In the combined (300 mg QD) and MAD2 (600 mg QD) cohorts, 73% (11 of 15) of
patients achieved a hemoglobin increase of greater than 1g/dL over baseline;
significant improvement in hematologic and hemolytic markers also include
decreased absolute reticulocytes (100%, or 15 of 15), decreased LDH levels (73%,
or 11 of 15) and decreased indirect bilirubin levels (93%, or 14 of 15). The
osmoscan and oxygenscan results from 14 patients showed a statistically
Initial results as of May 24, 2021, in the OLE cohort for eight patients
receiving once-daily etavopivat treatment (400 mg) for at least 2 weeks
indicated a hemoglobin increase of greater than 1 g/dL in 88% (7 of 8), with a
mean hemoglobin increase of 1.5 g/dL. Patient data indicated a durable response
for those patients receiving treatment beyond two weeks for up to 12 weeks, with
improved hematologic and hemolytic parameters. The improvement in RBC functional
health extended beyond the 12-week treatment period; in one patient, improved
sickle RBC deformability remained for up to four weeks after treatment
discontinuation. These initial OLE data support the combined MAD cohort results
and show that daily etavopivat treatment also significantly improved hematologic
and hemolytic parameters.
The safety profile in the OLE cohort was consistent with underlying disease. Of
note, two patients reported serious adverse events, including one vaso-occlusive
crisis and acute chest syndrome, which was not considered related to treatment
by the trial investigator. A deep-vein thrombosis (DVT) report was described as
The disclosure under this Item 8.01 contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, express or implied statements regarding the
Company's beliefs and expectations regarding: initial results to date for the
etavopivat open label extension cohort of the Company's Phase 1 clinical trial;
the therapeutic potential, clinical benefits and safety related to etavopivat;
whether initial results from the Company's clinical trials are predictive of
final trial results or future clinical studies; and the Company's planned
presentation of data at 2021 EHA Virtual Congress. The words "may," "will,"
"could," "would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management's
current expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or results to
differ materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related the Company's ability to
execute on its strategy; the therapeutic potential and safety of etavopivat; the
timing and completion of the Company's Phase 1 study of etavopivat and final
audit and quality controlled verification of initial data and related analyses;
the timing and success of the Company's Phase 2/3 Hibiscus Study of etavopivat
in SCD patients; positive results from initial data analyses may not be
predictive of final results; risks related to the Company's planned regulatory
submissions and developments; and other risks identified in the Company's SEC
filings, including those risks discussed under the heading "Risk Factors" in the
Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as
well as other risks detailed in the Company's subsequent filings with the SEC.
We caution you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. The Company disclaims any
obligation to publicly update or revise any such statements to reflect any
change in expectations or in events, conditions or circumstances on which any
such statements may be based, or that may affect the likelihood that actual
results will differ from those set forth in the forward-looking statements. Any
forward-looking statement included in this Item 8.01 speaks only as of the date
on which it was made. The Company undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Item 9.01. Exhibits
Press release issued by Forma Therapeutics Holdings, Inc. on June 11,
99.1 2021, furnished herewith.
99.2 Forma Therapeutics Holdings, Inc. Corporate Presentation, dated June 11,
2021, furnished herewith.
© Edgar Online, source Glimpses